Clinicopathological significance of BGP expression in non-small-cell lung carcinoma: Relationship with histological type, microvessel density and patients' survival

Pathology

Volumn 38, Issue 6, 2006, Pages 555-560

  Lee, Min Ki ^a   Kim, Jae Ho ^a   Lee, Chang Hun ^a   Kim, Jong Min ^b   Kang, Chi Duk ^a   Kim, Young Dae ^a   Choi, Kyung Un ^a   Kim, Hwal Woong ^a   Kim, Jee Yeon ^a   Park, Do Youn ^a   Sol, Mee Young ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Dong A University   (South Korea)

Author keywords

BGP; Brain type glycogen phosphorylase; Histology; Microvessel density; Non small cell lung carcinoma; NSCLC; Survival

Indexed keywords

GLYCOGEN PHOSPHORYLASE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; EPITHELIUM CELL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PATHOLOGY; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG TUMOR; METABOLISM; MICROCIRCULATION; MIDDLE AGED; MORTALITY; SEXUAL DEVELOPMENT; VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN PHOSPHORYLASE, BRAIN FORM; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG; LUNG NEOPLASMS; MALE; MICROCIRCULATION; MIDDLE AGED; PROGNOSIS; SEX CHARACTERISTICS; SURVIVAL RATE;

EID: 34247137242     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020601024029     Document Type: Article

References (30)

1. Maniscalco WM, Wilson CM, Gross I, Gobran L, Rooney SA, Warshaw JB. Development of glycogen and phospholipid metabolism in fetal and newborn rat lung. Biochim Biophys Acta 1978; 530: 333-46.
2. Newgard CB, Hwang PK, Fletterick RJ. The family of glycogen phosphorylases: structure and function. Crit Rev Biochem Mol Biol 1989; 24: 69-99.
3. Newgard CB, Littman DR, van Genderen C, Smith M, Fletterick RJ. Human brain glycogen phosphorylase. Cloning, sequence analysis, chromosomal mapping, tissue expression, and comparison with the human liver and muscle isozymes. J Biol Chem 1988; 263: 3850-7.
4. Shimada S, Maeno M, Akagi M, Hatayama I, Sato T, Sato K. Immunohistochemical detection of glycogen phosphorylase isoenzymes in rat and human tissues. Histochem J 1986; 18: 334-8.
5. Nakano K, Hwang PK, Fletterick RJ. Complete cDNA sequence for rabbit muscle glycogen phosphorylase. FEBS Lett 1986; 204: 283-7.
6. Sato K, Morris HP, Weinhouse S. Phosphorylase: a new isozyme in rat hepatic tumors and fetal liver. Science 1972; 178: 879-81.
7. Takashi M, Koshikawa T, Kurobe N, Kato K. Elevated concentrations of brain-type glycogen phosphorylase in renal cell carcinoma. Jpn J Cancer Res 1989; 80: 975-80.
8. Tashima S, Shimada S, Yamaguchi K, Tsuruta J, Ogawa M. Expression of brain-type glycogen phosphorylase is a potentially novel early biomarker in the carcinogenesis of human colorectal carcinomas. Am J Gastroenterol 2000; 95: 255-63.
9. Matsuzaki H, Shimada S, Uno K, Tsuruta J, Ogawa M. Novel subtyping of intestinal metaplasia in the human stomach: brain-type glycogen phosphorylase expression in the proliferative zone and its relationship with carcinogenesis. Am J Clin Pathol 1998; 109: 181-9.
10. Shimada S, Shiomori K, Honmyo U, Maeno M, Yagi Y, Ogawa M. BGP expression in gastric biopsies may predict the development of new lesions after local treatment for early gastric cancer. Gastric Cancer 2002; 5: 130-6.
11. Shimada S, Maeno M, Misumi A, Takano S, Akagi M. Antigen reversion of glycogen phosphorylase isoenzyme in carcinoma and proliferative zone of intestinal metaplasia of the human stomach. An immunohistochemical study. Gastroenterology 1987; 93: 35-40.
12. Sobin LH, Wittekind C. Lung. In: Sobin LH, Wittekind C (International Union Against Cancer [UICC]), editors. TNM Classification of Malignant Tumours. 5th ed. Baltimore: Wiley-Liss. 1997; 93-7.
13. Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung and Pleural Tumours. International Histological Classification of Tumours. 3rd ed. Berlin: Springer-Verlag.
14. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
15. Farrell PM, Bourbon JR. Fetal lung surfactant lipid synthesis from glycogen during organ culture. Biochim Biophys Acta 1986; 878: 159-67.
16. Rannels SR, Liu L, Weaver TE. Expression of glycogen phosphorylase isozymes in developing rat lung. Am J Physiol 1997; 273: L389-94.
17. Ito T, Noguchi Y, Udaka N, Kitamura H, Satoh S. Glucose transporter expression in developing fetal lungs and lung neoplasms. Histol Histopathol 1999; 14: 895-904.
18. Roach PJ. Glycogen and its metabolism. Curr Mol Med 2002; 2: 101-20.
19. Giatromanolaki A. Prognostic role of angiogenesis in non-small cell lung cancer. Anticancer Res 2001; 21: 4373-82.
20. Matsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R, Tanigawa N. Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg 1998; 65: 1405-9.
21. Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002; 87: 694-701.
22. Offersen BV, Pfeiffer P, Hamilton-Dutoit S, Overgaard J. Patterns of angiogenesis in non small-cell lung carcinoma. Cancer 2001; 91: 1500-9.
23. Tsoli E, Zacharatos P, Dasiou-Plakida D, et al. Growth index is independent of microvessel density in non-small-cell lung carcinomas. Hum Pathol 2002; 33: 812-8.
24. Hu J, Bianchi F, Ferguson M, et al. Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene 2005; 24: 1212-9.
25. Oyama T, Osaki T, Nose N, et al. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. Anticancer Res 2000; 20: 505-10.
26. Poleri C, Morero JL, Nieva B, et al. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Chest 2003; 123: 1858-67.
27. Nguyen VN, Mirejovsky P, Mirejovsky T, Melinova L, Mandys V. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem 2000; 102: 323-38.
28. Grossi F, Loprevite M, Chiaramondia M, et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer 2003; 39: 1242-50.
29. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997; 4: 339-43.
30. Schnier JB, Nishi K, Monks A, Gorin FA, Bradbury EM. Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression. Biochem Biophys Res Commun 2003; 309: 126-34.